M. von Lilienfeld-Toal , S. Agkatsev , A. Glasmacher , P. Reiß , S. Sen , A. Seltmann , S. Wolf
{"title":"字母re:癌症临床试验中的种族起源:高估还是低估?-对2020年至2022年期间FDA和EMA批准的癌症临床试验进行全面分析","authors":"M. von Lilienfeld-Toal , S. Agkatsev , A. Glasmacher , P. Reiß , S. Sen , A. Seltmann , S. Wolf","doi":"10.1016/j.esmoop.2025.105062","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 5","pages":"Article 105062"},"PeriodicalIF":7.1000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Letter re: Ethnic origin in cancer clinical trials: overrated or understated?—A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022\",\"authors\":\"M. von Lilienfeld-Toal , S. Agkatsev , A. Glasmacher , P. Reiß , S. Sen , A. Seltmann , S. Wolf\",\"doi\":\"10.1016/j.esmoop.2025.105062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11877,\"journal\":{\"name\":\"ESMO Open\",\"volume\":\"10 5\",\"pages\":\"Article 105062\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2025-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2059702925009317\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702925009317","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Letter re: Ethnic origin in cancer clinical trials: overrated or understated?—A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022
期刊介绍:
ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research.
ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO.
Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.